

## Special Issue

# Role of Epigenetic Modifications in Metabolic Diseases

### Message from the Guest Editor

Epigenetics refers to the study of changes in gene activity regulation and expression that are not dependent on the DNA sequence. Recent evidence suggests that environmental factors, as well as traditional cardiovascular risk factors, may trigger modifications within the epigenome, hence affecting the expression of oxidative and inflammatory genes, inducing metabolic changes. On the other hand, these epigenomic modifications may also serve as biomarkers for the risk of cardiovascular disease development and progression. We would like to invite you to contribute to this Special Issue of *Genes*, entitled “Role of Epigenetic Modifications in Metabolic Diseases”.

---

### Guest Editor

Dr. Charbel Abi Khalil

1. Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA
2. Department of Genetic Medicine, Weill Cornell Medicine-Qatar, Doha, Qatar

---

### Deadline for manuscript submissions

closed (17 September 2021)

G C A T  
T A C G  
G C A T

## Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.1  
CiteScore 5.9  
Indexed in PubMed



[mdpi.com/si/76148](https://mdpi.com/si/76148)

*Genes*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[genes@mdpi.com](mailto:genes@mdpi.com)

[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



G C A T  
T A C G  
G C A T

# Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.1  
CiteScore 5.9  
Indexed in PubMed



[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



## About the Journal

### Message from the Editor-in-Chief

*Genes* is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

---

### Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan  
Experimental Cancer Therapeutics, The University of Alabama at  
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-  
2182, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))